Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Studies have shown that many patients regain a significant portion of lost weight after discontinuing GLP-1 medications, highlighting the importance of sustainable lifestyle changes alongside pharmaceutical intervention
It targets the hormonal environment that makes recomposition possible
Mental Health Services and Typical BCBS Coverage Status (2026) Coverage varies by plan
Benefits are cumulative with regular treatment
Overall, the 90% CIs of the ERs for AUC for all concomitant medications were within the pre-specified interval
Here's a real-world comparison of the weight loss data we have: Semaglutide 2.4 mg (Wegovy): ~15% body weight loss at 68 weeks in the STEP 1 trial Tirzepatide 15 mg (Zepbound): ~22.5% body weight loss at 72 weeks in SURMOUNT-1 Retatrutide 12 mg: ~24.2% body weight loss at 48 weeks in Phase 2 (shorter trial, remember) Promising, but still unproven at scale
